Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2030-05-31
Target enrollment:
Participant gender:
Summary
This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus
trastuzumab in patients with tumors <8mm, node-negative, HER2-positive breast cancer.